STRATEGY

We are focusing our product development and commercialization resources on creating new best-in-class versions of existing drugs in large therapeutic categories such as cardiovascular disease, pain management and central nervous systems.  

We believe that a large number of FDA approved drugs may be suitable candidates for our MCP chemistry, which we intend to use to create new versions of these existing drugs. In addition, to expand the range of our proprietary product candidate opportunities we intend to combine MCP improved products with other marketed drugs to develop combination products with synergistic effects.

We intend to selectively pursue a strategy for generic products by developing generic versions of marketed drugs when we find that our MCP chemistry offers a unique opportunity to develop a patented product that is bioequivalent to an existing approved drug.